First-line treatment of women with advanced ovarian cancer: focus on bevacizumab

Ovarian cancer is the fifth most common cause of cancer death in women in Europe. Despite the progress, almost 70% of the patients relapse. The standard treatment is cytoreductive surgery followed by platinumtaxane chemotherapy; in patients with a disseminated disease, one option is neoadjuvant chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchetti, Claudia, Muzii, Ludovico, Romito, Alessia, Benedetti Panici, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371937/
https://www.ncbi.nlm.nih.gov/pubmed/30799939
http://dx.doi.org/10.2147/OTT.S155425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371937/
https://www.ncbi.nlm.nih.gov/pubmed/30799939
http://dx.doi.org/10.2147/OTT.S155425

Ejemplares similares